PARG-IN-4
PARG-IN-4 (Formula (A) ) is an orally available PARG inhibitor (EC50=1.9 nM) with cell membrane permeability. PARG-IN-4 can effectively inhibit tumor growth in mouse models. PARG-IN-4 can be used in cancer research[1].
Product Specifications
CAS Number
[2988890-20-4]
UNSPSC
12352005
Target
Apoptosis; Poly (ADP-ribose) Glycohydrolase (PARG)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/parg-in-4.html
Purity
98.86
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
CC1(CC1)NS(=O)(C2=CC(N3C[C@@H](N[C@H](C3)C)C)=C(C=NN4C5=NN=C(C(F)F)S5)C4=C2)=O
Molecular Formula
C20H25F2N7O2S2
Molecular Weight
497.59
References & Citations
[1]Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 4
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ERBB2, phosphorylated (Y1005) (ERBB2, HER2, MLN19, NEU, NGL, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340) (FITC) discontinued
Mouse Monoclonal HIST1H3A [p Ser10] Antibody (rPHH3/6824) [Alexa Fluor 647]
Recombinant Bacillus subtilis Phosphosulfolactate synthase (yitD)
Recombinant Bacillus subtilis Phosphosulfolactate synthase (yitD)
Recombinant Bacillus subtilis Phosphosulfolactate synthase (yitD)